Stealth Health Semaglutide

Semaglutide may cause thyroid C-cell tumors, including MTC, in rodents. It is unknown if it causes MTC in humans. Pancreatitis has been reported in patients treated with GLP-1 receptor agonists. Monitor for symptoms of acute pancreatitis. Gallbladder problems, including gallstones, have occurred. Acute kidney injury and worsening of chronic kidney failure have been reported. Monitor kidney function. Hypoglycemia may occur, especially when used with insulin or sulfonylureas. Inform your clinician if you have a history of diabetic retinopathy, as complications may worsen.

Do not use Stealth Health Semaglutide if you or your family have a history of medullary thyroid carcinoma (MTC). Do not use if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use if you have a history of serious allergic reaction to semaglutide or any components of the product. It is not indicated for use in patients with type 1 diabetes. It should not be used during pregnancy or breastfeeding.

The most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. These are often mild to moderate. They typically decrease over time as your body adjusts to the medication. Other common side effects may include headache, fatigue, and dyspepsia.

Semaglutide may slow gastric emptying. This can affect the absorption of orally administered medications. Use caution when taking oral medications that require rapid gastrointestinal absorption. Monitor blood glucose closely if co-administered with insulin or sulfonylureas, as the risk of hypoglycemia may increase. Adjustments to other diabetes medications may be necessary.

This information is not a complete list of all possible risks. Always discuss your full medical history with your healthcare provider. Report any new or worsening symptoms immediately. Do not share your medication with others. Keep out of reach of children. Store as directed.